$ACET
Adicet Bio, Inc.

2018 Q4 Form 10-Q Financial Statement

#000156459018029327 Filed on November 13, 2018

View on sec.gov

Income Statement

Concept 2018 Q4 2018 Q3 2017 Q3
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $2.010M $2.270M $610.0K
YoY Change 175.34% 272.13%
% of Gross Profit
Research & Development $4.350M $6.765M $3.333M
YoY Change -35.94% 102.97%
% of Gross Profit
Depreciation & Amortization $20.00K $24.00K $3.000K
YoY Change 100.0% 700.0%
% of Gross Profit
Operating Expenses $6.360M $9.032M $3.333M
YoY Change -15.43% 170.99%
Operating Profit -$6.360M -$9.032M -$3.945M
YoY Change -15.46% 128.95%
Interest Expense
YoY Change
% of Operating Profit
Other Income/Expense, Net $630.0K $625.0K $635.0K
YoY Change -104.06% -1.57%
Pretax Income -$5.730M -$8.407M -$3.310M
YoY Change -75.14% 153.99%
Income Tax $30.00K $0.00
% Of Pretax Income
Net Earnings -$5.757M -$8.407M -$3.310M
YoY Change -75.03% 153.99%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share -$1.436M -$2.097M -$825.4K
COMMON SHARES
Basic Shares Outstanding 28.06M
Diluted Shares Outstanding

Balance Sheet

Concept 2018 Q4 2018 Q3 2017 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $108.0M $115.4M $4.000M
YoY Change 102.63% 2785.0%
Cash & Equivalents $9.475M $22.86M $3.965M
Short-Term Investments $101.0M $92.50M
Other Short-Term Assets $15.00K $24.00K $200.0K
YoY Change -82.14% -88.0%
Inventory
Prepaid Expenses $1.491M $1.621M
Receivables
Other Receivables
Total Short-Term Assets $109.5M $117.0M $4.200M
YoY Change 98.6% 2686.26%
LONG-TERM ASSETS
Property, Plant & Equipment $321.0K $319.0K $0.00
YoY Change 723.08%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $100.0K $100.0K
YoY Change
Total Long-Term Assets $405.0K $403.0K $0.00
YoY Change 938.46%
TOTAL ASSETS
Total Short-Term Assets $109.5M $117.0M $4.200M
Total Long-Term Assets $405.0K $403.0K $0.00
Total Assets $109.9M $117.4M $4.200M
YoY Change 99.19% 2695.86%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $2.989M $4.201M $1.100M
YoY Change 97.29% 281.91%
Accrued Expenses $2.727M $3.363M $1.000M
YoY Change -31.6% 236.3%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $5.716M $8.064M $3.500M
YoY Change 3.89% 130.4%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $19.00K $22.00K
YoY Change
Total Long-Term Liabilities $19.00K $22.00K $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $5.716M $8.064M $3.500M
Total Long-Term Liabilities $19.00K $22.00K $0.00
Total Liabilities $5.735M $8.086M $3.500M
YoY Change 4.23% 131.03%
SHAREHOLDERS EQUITY
Retained Earnings -$71.39M -$65.64M
YoY Change 111.35%
Common Stock $175.6M $3.000K
YoY Change 17563700.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$33.52M $109.3M $700.0K
YoY Change
Total Liabilities & Shareholders Equity $109.9M $117.4M $4.200M
YoY Change 99.19% 2695.86%

Cashflow Statement

Concept 2018 Q4 2018 Q3 2017 Q3
OPERATING ACTIVITIES
Net Income -$5.757M -$8.407M -$3.310M
YoY Change -75.03% 153.99%
Depreciation, Depletion And Amortization $20.00K $24.00K $3.000K
YoY Change 100.0% 700.0%
Cash From Operating Activities -$7.720M -$10.72M -$3.860M
YoY Change 54.71% 177.72%
INVESTING ACTIVITIES
Capital Expenditures -$30.00K -$30.00K $10.00K
YoY Change -400.0%
Acquisitions
YoY Change
Other Investing Activities -$8.060M -$17.75M
YoY Change
Cash From Investing Activities -$8.090M -$17.78M $10.00K
YoY Change -177900.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 0.000 0.000 4.500M
YoY Change -100.0% -100.0%
NET CHANGE
Cash From Operating Activities -7.720M -10.72M -3.860M
Cash From Investing Activities -8.090M -17.78M 10.00K
Cash From Financing Activities 0.000 0.000 4.500M
Net Change In Cash -15.81M -28.50M 650.0K
YoY Change -132.01% -4484.62%
FREE CASH FLOW
Cash From Operating Activities -$7.720M -$10.72M -$3.860M
Capital Expenditures -$30.00K -$30.00K $10.00K
Free Cash Flow -$7.690M -$10.69M -$3.870M
YoY Change 54.11% 176.23%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Document Type
DocumentType
10-Q
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Entity Central Index Key
EntityCentralIndexKey
0001720580
dei Document Period End Date
DocumentPeriodEndDate
2018-09-30
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2018
CY2018Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2018Q3 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
92522000
CY2018Q3 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
1621000
dei Amendment Flag
AmendmentFlag
false
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
dei Trading Symbol
TradingSymbol
TORC
dei Entity Ex Transition Period
EntityExTransitionPeriod
false
dei Entity Small Business
EntitySmallBusiness
false
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-2.79
CY2017Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-3310000
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.23
CY2018Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-8453000
CY2017Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
4408094
CY2018Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
6765000
CY2018Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2267000
CY2018Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-9032000
CY2017Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2017Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
30000000
dei Entity Registrant Name
EntityRegistrantName
resTORbio, Inc.
CY2017Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
5659089
CY2017Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
5659089
CY2018Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.30
CY2018Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
28055344
CY2018Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
22856000
CY2017Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
53349000
CY2017Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
792000
CY2018Q3 us-gaap Other Assets Current
OtherAssetsCurrent
24000
CY2017Q4 us-gaap Other Assets Current
OtherAssetsCurrent
84000
CY2018Q3 us-gaap Assets Current
AssetsCurrent
117023000
CY2017Q4 us-gaap Assets Current
AssetsCurrent
55154000
CY2018Q3 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
84000
CY2017Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
39000
CY2017Q4 us-gaap Assets
Assets
55193000
CY2017Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1515000
CY2017Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
3987000
CY2018Q3 us-gaap Liabilities Current
LiabilitiesCurrent
8064000
CY2017Q4 us-gaap Liabilities Current
LiabilitiesCurrent
5502000
CY2018Q3 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
22000
CY2017Q4 us-gaap Liabilities
Liabilities
5502000
CY2017Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2018Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
28046723
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-10724000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-76000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
10047000
CY2017Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-3945000
CY2018Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
625000
CY2017Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.75
CY2017Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
635000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
1488000
CY2018Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-8407000
CY2017Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-3310000
CY2018Q3 us-gaap Net Income Loss
NetIncomeLoss
-8407000
CY2017Q3 us-gaap Net Income Loss
NetIncomeLoss
-3310000
us-gaap Net Income Loss
NetIncomeLoss
-31857000
CY2018Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2018Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2018Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2018Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2018Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2018Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000
CY2018Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
28048315
CY2018Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
28048315
CY2017Q4 us-gaap Deferred Costs Current
DeferredCostsCurrent
929000
CY2018Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
319000
CY2018Q3 us-gaap Assets
Assets
117426000
CY2018Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
4201000
CY2018Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
3363000
CY2018Q3 us-gaap Customer Advances Current
CustomerAdvancesCurrent
500000
CY2018Q3 us-gaap Liabilities
Liabilities
8086000
CY2018Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2018Q3 us-gaap Preferred Stock Value
PreferredStockValue
CY2017Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2018Q3 us-gaap Common Stock Value
CommonStockValue
3000
CY2017Q4 us-gaap Common Stock Value
CommonStockValue
1000
CY2018Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
175049000
CY2017Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
1849000
CY2018Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-65636000
CY2017Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-33779000
CY2018Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-76000
CY2018Q3 us-gaap Stockholders Equity
StockholdersEquity
109340000
CY2017Q4 us-gaap Stockholders Equity
StockholdersEquity
-31929000
CY2018Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
117426000
CY2017Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
55193000
CY2018Q3 us-gaap Due To Related Parties Current
DueToRelatedPartiesCurrent
37000
CY2017Q4 us-gaap Due To Related Parties Current
DueToRelatedPartiesCurrent
32000
CY2017Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2017Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
0
CY2017Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2017Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2018Q3 torc Common Stock Shares Vested
CommonStockSharesVested
28046815
CY2017Q4 torc Common Stock Shares Vested
CommonStockSharesVested
4562640
CY2017Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
3333000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
26716000
CY2017Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
612000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
6629000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1312000
CY2018Q3 us-gaap Costs And Expenses
CostsAndExpenses
9032000
CY2017Q3 us-gaap Costs And Expenses
CostsAndExpenses
3945000
us-gaap Costs And Expenses
CostsAndExpenses
33345000
us-gaap Costs And Expenses
CostsAndExpenses
11359000
us-gaap Operating Income Loss
OperatingIncomeLoss
-33345000
us-gaap Operating Income Loss
OperatingIncomeLoss
-11359000
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
25895933
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
3839306
CY2018Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-46000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-31933000
us-gaap Profit Loss
ProfitLoss
-31857000
us-gaap Profit Loss
ProfitLoss
-10724000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
305000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
55000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
3000
us-gaap Share Based Compensation
ShareBasedCompensation
2212000
us-gaap Share Based Compensation
ShareBasedCompensation
301000
torc Change In Fair Value Of Tranche Liability
ChangeInFairValueOfTrancheLiability
-635000
torc Expense Related To Acquisition Of Intellectual Property
ExpenseRelatedToAcquisitionOfIntellectualProperty
3157000
us-gaap Increase Decrease In Restricted Cash
IncreaseDecreaseInRestrictedCash
84000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
769000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
635000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-31857000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-10724000
us-gaap Net Income Loss
NetIncomeLoss
-10724000
CY2017Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
44000
CY2017Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
5000
CY2018Q3 torc Accrued Research And Development Expenses Current
AccruedResearchAndDevelopmentExpensesCurrent
2214000
CY2017Q4 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
17736568
us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
22000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
214000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
2807000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
1094000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-386000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
1022000
us-gaap Increase Decrease In Customer Advances
IncreaseDecreaseInCustomerAdvances
500000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-27805000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-5996000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
333000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
39000
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
92293000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-92626000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-39000
us-gaap Proceeds From Issuance Of Redeemable Convertible Preferred Stock
ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock
10000000
us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
89938000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
89938000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
10000000
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-30493000
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
3965000
CY2017Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
3965000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
2000
us-gaap Conversion Of Stock Amount Converted1
ConversionOfStockAmountConverted1
81620000
us-gaap Use Of Estimates
UseOfEstimates
<div> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Use of Estimates<font style="font-weight:normal;font-style:normal;"> </font></p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:7.94%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities, as of the date of the condensed consolidated financial statements, and the reported amounts of any expenses during the reporting period. On an ongoing basis, management evaluates its estimates, including those related to accrued liabilities, income taxes, and stock-based compensation expense. Management bases its estimates on historical experience, and on various other market-specific relevant assumptions that management believes to be reasonable, under the circumstances. Actual results may differ from those estimates or assumptions. </p></div>
CY2018Q1 us-gaap Stockholders Equity Reverse Stock Split
StockholdersEquityReverseStockSplit
one-for-1.2804
CY2018Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000
dei Entity Incorporation Date Of Incorporation
EntityIncorporationDateOfIncorporation
2016-07-05
CY2018Q1 torc Effective Date Of Reverse Stock Split
EffectiveDateOfReverseStockSplit
2018-01-12
CY2018Q3 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
115400000
CY2017Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
0
CY2018Q3 us-gaap Deferred Offering Costs
DeferredOfferingCosts
0
CY2017Q4 us-gaap Deferred Offering Costs
DeferredOfferingCosts
900000
CY2018Q3 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
92598000
CY2018Q3 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
76000
CY2018Q3 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
92522000
CY2017Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
0
CY2018Q3 us-gaap Available For Sale Securities Debt Maturities Within One Year Amortized Cost
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost
92598000
CY2018Q3 us-gaap Available For Sale Securities Debt Maturities Within One Year Fair Value
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
92522000
CY2018Q3 us-gaap Available For Sale Securities Debt Maturities Single Maturity Date
AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate
92522000
CY2018Q3 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
379000
CY2018Q3 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
60000
CY2018Q3 us-gaap Depreciation
Depreciation
24000
CY2017Q3 us-gaap Depreciation
Depreciation
3000
us-gaap Depreciation
Depreciation
55000
us-gaap Depreciation
Depreciation
3000
CY2018Q3 torc Accrued Wages Bonuses Vacation And Payroll Taxes Current
AccruedWagesBonusesVacationAndPayrollTaxesCurrent
789000
CY2017Q4 torc Accrued Wages Bonuses Vacation And Payroll Taxes Current
AccruedWagesBonusesVacationAndPayrollTaxesCurrent
394000
CY2017Q4 torc Accrued Research And Development Expenses Current
AccruedResearchAndDevelopmentExpensesCurrent
3250000
CY2017Q4 torc Deferred Offering Costs Current
DeferredOfferingCostsCurrent
238000
CY2018Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
360000
CY2017Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
105000
CY2017Q4 us-gaap Temporary Equity Shares Authorized
TemporaryEquitySharesAuthorized
20320667
CY2018Q3 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
2780278
CY2018Q3 us-gaap Litigation Reserve
LitigationReserve
0
CY2017Q4 us-gaap Litigation Reserve
LitigationReserve
0
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1066678
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
6175031

Files In Submission

Name View Source Status
0001564590-18-029327-index-headers.html Edgar Link pending
0001564590-18-029327-index.html Edgar Link pending
0001564590-18-029327.txt Edgar Link pending
0001564590-18-029327-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
torc-10q_20180930.htm Edgar Link pending
torc-20180930.xml Edgar Link completed
torc-20180930.xsd Edgar Link pending
torc-20180930_cal.xml Edgar Link unprocessable
torc-20180930_def.xml Edgar Link unprocessable
torc-20180930_lab.xml Edgar Link unprocessable
torc-20180930_pre.xml Edgar Link unprocessable
torc-ex101_41.htm Edgar Link pending
torc-ex311_7.htm Edgar Link pending
torc-ex312_8.htm Edgar Link pending
torc-ex321_6.htm Edgar Link pending